IsoRay, Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 80th Annual Meeting of the American Association of Neurological Surgeons (AANS). The annual meeting will take place April 14-18, 2012 in Miami Beach, Florida at the Miami Beach Convention Center. IsoRay’s participation marks the Company's formal introduction to the neuroscience community. At IsoRay’s booth (Booth 952), a series of discussion groups and presentations will be taking place led by a number of thought leaders from major medical centers. In addition to demonstrating the GliaSite® radiation system, the booth will also feature slide shows, videos, and working demonstrations of the application of mesh with embedded seeds. IsoRay has exclusive worldwide distribution rights for the GliaSite® radiation therapy system. GliaSite® is an innovative, significant advance over previous brain cancer treatments. Doctors are able to use the system to directly place a specified dosage of liquid radiation in areas where cancer is most likely to still remain after completion of surgical brain tumor removal. The ability to precisely place a specified dosage of this form of radiation means there is less likelihood for damage to occur to healthy brain tissue compared to other alternative treatments. Importantly, the GliaSite® radiation treatment impacts the ability of the tumor to recur which means crucial benefits for patients in longevity as well as quality of life. In another key development, yet another leading institution has adopted the GliaSite® radiation therapy system. The University of Maryland has just completed its first treatment of a brain cancer patient using GliaSite®. According to IsoRay CEO Dwight Babcock some 65,000 new cases of primary brain tumors are expected to be diagnosed this year amongst all age groups. "Brain cancer doesn't discriminate. It afflicts men, women, and children with devastating impact. GliaSite® is showing dramatic results in treating a variety of brain cancers and we are confident that physicians will quickly adopt this vital treatment."
IsoRay is also the exclusive manufacturer of Cesium-131. The pioneering brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years. Cesium-131 allows for the internal radiation treatment of many different cancers because of its unique combination of high energy (its distinctive tissue penetrating capability reaching just far enough to treat the cancer) and its 9.7 day half-life (its matchless speed in giving off therapeutic radiation). In addition to its CMS codes, Cesium-131 is FDA-cleared for the treatment of brain cancer, lung cancer, head and neck cancer, prostate cancer, gynecological cancer, colorectal cancer, and ocular melanoma.To learn more about the 2012 AANS Annual Scientific Meeting, please visit http://www.aans.org/Annual%20Meeting/2012.aspx About IsoRay IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com . Follow us on Twitter @Isoray and join us on Facebook/Isoray . Safe Harbor Statement Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, the advantages of the GliaSite® delivery system, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether there will be demand for GliaSite® at expected or historic levels, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with the GliaSite® delivery system or with Cesium-131 are favorable and in line with the conclusions of clinical studies, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer whether with the GliaSite® delivery system or in another delivery system, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC.